Not Tagged
Not Tagged
['breast']
a hr+ her2+ breast cancer patient with 16 prior lines of therapy including multiple anti-her2 modalities received df1001 monotherapy &amp; experienced a rapid and durable partial response lasting 5 months #asco23
We are a clinical-stage company developing drugs targeting natural killer cells & other cells of the innate immune system, to eliminate cancer & other diseases.